FDA Approval Granted for Commercial Manufacturing at Rezon Bio's Warsaw-Duchnice Facility
Rezon Bio announces that its Warsaw-Duchnice facility has received approval from the U.S. Food and Drug Administration (FDA) for the commercial manufacturing of a biosimilar. This milestone represents an important step in the continued development of Rezon Bio’s global manufacturing network and reflects the company’s focus on building robust, compliant, and reliable capabilities to support biologic therapies for patients worldwide.
Rezon Bio Launches as a European Biologics CDMO Combining Cost Efficiency and Digital Innovation
Rezon Bio today announced its launch as a European contract development and manufacturing organization (CDMO) for biologics. It enters the market as a new brand, but builds on a proven legacy of advancing biologics from gene to global commercialization through established partners.
